biostudies-literatureGuillen NFundació Docència i Recerca Mútua de TerrassaInstituto de Salud Carlos IIINIA NIH HHSDiputació de LleidaFoundation for the National Institutes of HealthFundación BBVADepartament de Salut, Generalitat de CatalunyaUniversitat de BarcelonaFundació la Marató de TV3Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas257-266https://www.ebi.ac.uk/biostudies/studies/S-EPMC11799063biostudies-literatureUnknown275(1)Core Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarkers have shown incomplete agreement with amyloid-positron emission tomography (PET). Our goal was to analyze the agreement between AD CSF biomarkers and amyloid-PET in a multicenter study. Retrospective multicenter study (5 centers). Participants who underwent both CSF biomarkers and amyloid-PET scan within 18 months were included. Clinical diagnoses were made according to latest diagnostic criteria by the attending clinicians. CSF Amyloid Beta_1-42 (Aβ_1-42, A), phosphorliated tau 181 (pTau181, T) and total tau (tTau, N) biomarkers were considered normal (-) or abnormal ( +) according to cutoffs of each center. Amyloid-PET was visually classified as positive/negative. Agreement between CSF biomarkers and amEuropean archives of psychiatry and clinical neuroscienceAgreement of cerebrospinal fluid biomarkers and amyloid-PET in a multicenter study.PMC11799063SLT006/17/125PERIS SLT002/16/408Program 1PI19/00449AGAURPERIS 2019 SLT008/18/0005020141210RF1 AG061566PI20/01473SLT006/17/119PI14/011262022INT19/00016PIRS2021Alzheimer DiseaseFI20/00076PI17/01019PI17/01896PERIS 2016-2020 SLT008/18/0006120142610AC19/00103R21AG056974PI18/00435R01AG0615661R01AG056850-01A1Alvarez ILourdes Ispierto MAlcolea DLlado ACarnes-Vendrell AVilas DCulell NGuillen NPuig-Pijoan ABalasa MFortea JPinol-Ripoll GContador JFernandez-Lebrero ABuongiorno MLleo ASanchez-Valle RfalseAgreement of cerebrospinal fluid biomarkers and amyloid-PET in a multicenter study.Core Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarkers have shown incomplete agreement with amyloid-positron emission tomography (PET). Our goal was to analyze the agreement between AD CSF biomarkers and amyloid-PET in a multicenter study. Retrospective multicenter study (5 centers). Participants who underwent both CSF biomarkers and amyloid-PET scan within 18 months were included. Clinical diagnoses were made according to latest diagnostic criteria by the attending clinicians. CSF Amyloid Beta_1-42 (Aβ_1-42, A), phosphorliated tau 181 (pTau181, T) and total tau (tTau, N) biomarkers were considered normal (-) or abnormal ( +) according to cutoffs of each center. Amyloid-PET was visually classified as positive/negative. Agreement between CSF biomarkers and am2025-01-01T00:00:00Z2025 Feb2025-04-22T12:38:08.899Z2025-04-06T00:20:36.724ZS-EPMC117990633789856710.1007/s00406-023-01701-y